Guest introduction
Quinne Feng, former assistant professor of pathology at the University of Washington School of Medicine in Seattle. Later, she co-founded FidaLab with Cheng Xie. In the early days, the company's business focused on the use of modern molecular biology technology to detect infectious diseases and cancer-causing viruses. It was awarded the 2023 Best Service Award by the Washington State Medical Association (WHCA) for providing fast and accurate diagnosis.
Everyone wants to live a healthy long life. The main factors affecting life expectancy are several common diseases (such as cardiovascular disease, diabetes, Alzheimer's disease, etc.). These diseases have sub-clinical lesions that last for years or even decades, so middle-aged and even young people may suffer from sub-clinical lesions without knowing it. In view of this, the company is currently mainly committed to using early diagnosis of sub-clinical biochemical changes, combined with the detection of potential pathogenic genes, guiding healthy living and monitoring the effects of fitness exercises to achieve the goal of healthy longevity. The current US medical system is still mainly based on treatment, and sub-clinical lesions are almost completely ignored. But once symptoms appear, the condition is irreversible and cannot be cured. So we focus on early detection, early detection of lesions, and timely preventive measures to avoid the occurrence of diseases.
Quinne Feng's Academic Background
Bachelor's degree in Bioengineering, Fudan University
PhD in Molecular Biology, Johns Hopkins University
Postdoctoral fellow, Massachusetts Institute of Technology
Content
Personalized health tests based on genetic testing;
Biochemical screening of sub-disease states;
Biochemical monitoring of fitness exercise effects;
Oral health to prevent major systemic diseases.
Comments